Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

byBenzinga Newsdesk

November 17, 2022

1 minute read

Monness, Crespi, Hardt analyst Brian White downgrades Salesforce (NYSE:CRM) from Buy to Neutral.

News

China Green Agriculture Says Co. Received Letter From NYSE, Says Co. Will Be Removed From NYSE’s Late Filers’ List Effective July 5, 2022

By Michael Horton

Today, 9:12 AM

China Green Agriculture, Inc. (NYSE:CGA) ("China Green Agriculture" or the "Company") announced today that, on July 5, 2022 the Company received a notice letter from the New York Stock Exchange

CGA

FDA
News

AstraZeneca Announced PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

By Charles Gross

Today, 9:12 AM

The Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older.

AZN

Mid-Day Market Update: Nasdaq Jumps 350 Points; CarParts.com Shares Drop

By Lisa Levin

Today, 9:12 AM

U.S. stocks traded higher midway through trading, with the Nasdaq jumping 350 points on Wednesday.

BEKE

Roth Capital Initiates Coverage On Newly Listed Unicycive

By Vandana Singh

Today, 9:12 AM

Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target. Analyst Elemer Piros says that the Company could submit…

UNCY

Monness, Crespi, Hardt Downgrades Salesforce to Neutral

Related Posts

China Green Agriculture Says Co. Received Letter From NYSE, Says Co. Will Be Removed From NYSE’s Late Filers’ List Effective July 5, 2022

AstraZeneca Announced PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

Mid-Day Market Update: Nasdaq Jumps 350 Points; CarParts.com Shares Drop

Roth Capital Initiates Coverage On Newly Listed Unicycive